Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News   Jan 11, 2018 | Original story from National Institutes of Health

 
Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

The round, spiked objects at center are MERS coronavirus particles. Credit: NIAID

 
 
 

RELATED ARTICLES

Deficiency of Innate Immune Adaptor TRIF Linked to Neurodegeneration

News

Research has revealed that deficiency of the innate immune adaptor TRIF, which is essential for certain Toll-like receptor signaling cascades, significantly shortened survival time of ALS mice.

READ MORE

Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine Yields

News

Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.

READ MORE

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE